Know Your Ports - Oncology Nursing News
2017年12月21日 · Throughout the course of treatment, many patients with cancer receive chemotherapy, intravenous fluids, antibiotics, and much more via central venous catheters such as Mediports.
Oncology Nursing News
Panelists discuss how amivantamab’s dual targeting of EGFR and MET may address resistance mechanisms and unmet needs in EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Dr Scott highlighting its potential clinical benefits, while Squires shares insights on managing the adverse event profile and strategies for managing adverse effects in patients receiving intravenous (IV ...
Oncology Drugs Approved by the FDA in August 2024 - Oncology …
2024年9月3日 · Throughout the month of August, several cancer therapies have been approved by the FDA for diseases including non-small cell lung cancer (NSCLC), cutaneous T-cell lymphoma, astrocytoma and oligodendroglioma, and endometrial cancer.
Low-Dose Tamoxifen Shows Continued Efficacy in Adjuvant …
2023年2月17日 · Tamoxifen, at a dose of 5 mg daily (babytam), continued to show a benefit over placebo in reducing the risk of recurrence from invasive breast cancers and ductal carcinoma in situ (DCIS) in women with breast intraepithelial neoplasia in a 10-year follow-up of the TAM-01 trial (NCT01357772).
ctDNA Has High Sensitivity ESR1 Mutations in Metastatic Breast …
2024年10月14日 · After a patient with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer experiences disease progression on frontline therapy, it is essential that they be tested for an ESR1 mutation. ctDNA testing is the best way to do that, according to a physician assistant from Maimonides Cancer Center.. About ESR1 Mutations in Metastatic Breast Cancer
FDA Delays Decision Dates for Sotorasib and Obeticholic Acid
2024年10月23日 · The FDA pushed back Prescription Drug User Fee Act (PDUFA) dates for sotorasib (Lumakras) and obeticholic acid (Ocaliva) in patients with metastatic colorectal cancer and primary biliary cholangitis, respectively. 1 In May 2021, the FDA granted accelerated approval to sotorasib for the treatment of patients with KRAS G12C mutated non–small cell lung cancer. 2 However, in December 2023, a ...
ASCO Recommends Abemaciclib for High-Risk HR+, HER2- Breast …
2024年10月24日 · The American Society of Clinical Oncology (ASCO) recently announced guidelines outlining a preference for abemaciclib (Verzenio) over ribociclib (Kisqali) for the treatment of patients with node-positive, high-risk, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. 1. The recommendation is based on findings from the monarchE (NCT03155997 ...
Belantamab Mafodotin, KRd Is Promising in Relapsed/Refractory …
2024年10月2日 · Belantamab mafodotin-blmf (Blenrep) plus carfilzomib, lenalidomide (Revlimid), and dexamethasone (a regimen known as KRd) demonstrated early evidence of deep responses, as well as a manageable adverse event profile in previously treated patients with multiple myeloma, according to data from a phase 1 trial (NCT04822337), presented at the 21st International Myeloma Society Annual Meeting. 1
PD-L1 CPS Score Could Direct Treatment Decisions in Recurrent ...
2022年4月1日 · PD-L1 combined positive score (CPS) may serve to predict whether a patient with PD-L1–expressing recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) will receive optimal benefit with pembrolizumab (Keytruda) alone vs in combination with chemotherapy or with cetuximab (Erbitux) plus chemotherapy, according to an efficacy subgroup analysis of the phase 3 KEYNOTE-048 trial ...
Oncology Drugs Approved by the FDA in June 2024 - Oncology …
2024年7月1日 · Throughout the month of June, several cancer therapies have received FDA approval for diseases including thyroid cancer, myelodysplastic syndrome (MDS), colorectal cancer (CRC), endometrial cancer, and follicular lymphoma (FL).